Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | USP19 | O94966 | 2/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282038 | 0.93 | HCRTR1 (0.38) | HCRTR1HCRTR2SIGMAR1USP19PPARG | |
| SCHEMBL4293902 | 0.89 | HCRTR1 (0.38) | HCRTR1HCRTR2USP19PPARGPPARA | |
| SCHEMBL4281825 | 0.88 | HCRTR1 (0.38) | HCRTR1HCRTR2USP19 | |
| SCHEMBL4289627 | 0.87 | HCRTR1 (0.36) | HCRTR1HCRTR2USP19 | |
| SCHEMBL4286361 | 0.87 | HCRTR2 (0.38) | HCRTR1HCRTR2USP19 | |
| SCHEMBL4285006 | 0.87 | MEN1 (0.36) | HCRTR1HCRTR2USP19 | |
| SCHEMBL4284952 | 0.86 | NPC1 (0.37) | HCRTR1HCRTR2USP19 | |
| SCHEMBL4287556 | 0.86 | HCRTR1 (0.35) | HCRTR1HCRTR2USP19 | |
| SCHEMBL4287922 | 0.86 | HCRTR1 (0.42) | HCRTR1HCRTR2USP19 | |
| SCHEMBL4287621 | 0.86 | HCRTR1 (0.41) | HCRTR1HCRTR2USP19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885SIGMAR1 3163/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885SIGMAR1 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.